BIO is pleased to feature Jan Lundberg of Eli Lilly as this year’s fireside chat speaker! Fireside chats feature candid discussions between biopharma CEOs and Wall Street analysts or journalists. Hear about recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014.

Time and Date: October 9, 2013 10:30am - 11:25am
Location: Twin Peaks North & South

 Jan M. Lundberg, Ph.D, Eli Lilly
 Executive Vice President, Science and Technology
 President, Lilly Research Laboratories
 

Jan M. Lundberg, Ph.D. is Executive Vice President for Science and Technology and President of Lilly Research Laboratories (LRL). He is also a member of the company’s executive committee.

Dr. Lundberg joined Eli Lilly and Company January, 2010, with responsibility for Research and the Development Center of Excellence at Lilly. Prior to assuming his position at Lilly, Dr. Lundberg served as Global Head of Discovery Research at AstraZeneca for ten years and was a member of the senior executive team. He was involved with numerous candidate drug nominations, development projects and support for marketed products.

Dr. Lundberg has served on several committees which include Chairman, PhD and post doc programme at the Karolinska Institute, Evaluation Committee for the Swedish Medical Research Council, Executive Advisory Board, the Swedish Medical Products Agency Registration of New Drugs (part of EMEA), and EFPIA Research head group generating the Innovative Medicines Initiative (IMI), a major public private partnership with the European Union. He serves on PhRMA’s Science and Regulatory Committee and is on the board of Biotechnology Industry Organization (BIO) and BioCrossroads.

Simone Fishburn, Senior Editor at BioCentury Publications, will lead the fireside chat discussion.

Simone Fishburn, PhD
Senior Editor
BioCentury Publications

Simone serves as Senior Editor in the SciBX joint publishing venture with Nature Publishing Group. Prior to joining BioCentury in 2013, Simone worked as a translational scientist in the biotech industry, including nine years in preclinical drug development at Nektar Therapeutics. Simone holds a Ph.D. in molecular pharmacology from the Weizmann Institute of Science in Israel, and an M.A. and B.A. in Pharmacology from Cambridge University. 

Explore our program and see the full list of events at the 2013 BIO Investor Forum by clicking here.